Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.68 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.63 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.63 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.62 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.59 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 2/20 | 0.55 |
| ▸ | NAAA | Q02083 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13599952 | 0.89 | MEN1 (0.63) | MAOBLTB4RLTB4R2NR4A2CYP4F2 | |
| SCHEMBL9079802 | 0.87 | MRGPRX4 (0.56) | MAOBLTB4RLTB4R2FFAR1 | |
| SCHEMBL954459 | 0.87 | NR4A2 (0.66) | MAOBLTB4RLTB4R2NR4A2CYP4F2 | |
| SCHEMBL9379190 | 0.87 | CYP4F2 (0.63) | MAOBLTB4RLTB4R2NR4A2CYP4F2 | |
| SCHEMBL3660617 | 0.84 | FFAR1 (0.66) | MAOBLTB4RLTB4R2NR4A2CYP4F2 | |
| SCHEMBL2848161 | 0.84 | MAOB (0.60) | MAOBLTB4RLTB4R2NR4A2CYP4F2 | |
| SCHEMBL13599950 | 0.84 | MAOB (0.55) | MAOBLTB4RLTB4R2NR4A2CYP4F2 | |
| SCHEMBL8986815 | 0.84 | LMNA (0.61) | MAOBLTB4RLTB4R2FFAR1 | |
| SCHEMBL2790268 | 0.84 | NR4A2 (0.62) | MAOBLTB4RLTB4R2NR4A2CYP4F2 | |
| SCHEMBL13347806 | 0.84 | CYP4F2 (0.59) | MAOBLTB4RLTB4R2NR4A2CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3947342-A1 | PROCESS FOR THE PREPARATION OF TAPENTADOL AND ANALOGS THEREOF | Council of Scientific and Industrial Research (IN) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020194326-A1 | PROCESS FOR THE PREPARATION OF TAPENTADOL AND ANALOGS THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2020-10-01 | — | — | WO | disclosed |
| EP-3063125-A1 | NOVEL INTERMEDIATE OF TAPENTADOL | Sun Pharma Advanced Research Company (IN) | 2016-09-07 | — | — | EP | disclosed |
| WO-2015075744-A1 | NOVEL INTERMEDIATE OF TAPENTADOL | SUN PHARMA ADVANCED RESEARCH COMPANY (IN) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015075678-A1 | A NOVEL PROCESS FOR THE PREPARATION OF 1-PHENYL-3-AMINOPROPANE DERIVATIVES | UNIMARK REMEDIES LTD. (IN) | 2015-05-28 | — | — | WO | disclosed |
| WO-2014061821-A1 | GRB10 INTERACTING GYF PROTEIN 2 MODULATOR | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2014-04-24 | — | — | WO | disclosed |
| WO-2013105109-A1 | PROCESS FOR THE PREPARATION OF TAPENTADOL | INDOCO REMEDIES LIMITED (IN) | 2013-07-18 | — | — | WO | disclosed |
| EP-2606030-A1 | PROCESS FOR THE PREPARATION OF TAPENTADOL | Indoco Remedies Limited (IN) | 2013-06-26 | — | — | EP | disclosed |
| US-20120270847-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIATES AND USES THEREOF | SHIRE LLC (US) | 2012-10-25 | — | — | US | disclosed |
| WO-2012023147-A1 | PROCESS FOR THE PREPARATION OF TAPENTADOL | INDOCO REMEDIES LIMITED (IN) | 2012-02-23 | — | — | WO | disclosed |
| US-20110015182-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015182-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | OPRL1, OPRM1, DNPEP | MAOB 1187/4885LTB4R 1948/4885LTB4R2 2229/4885 |
| US-20120270847-A1 | NOVEL CARBAMATE AMINO ACID AND PEPTIDE PRODRUGS OF OPIATES AND USES THEREOF | OPRL1, OPRM1, DNPEP | MAOB 1278/4885LTB4R 1925/4885LTB4R2 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.